Get the Stockscreener App
7.915
1.91%
0.045
After Hours:
7.93
0.015
+0.19%
Anbio Biotechnology stock is traded at $7.915, with a volume of 19,176.
It is up +1.91% in the last 24 hours and up +24.73% over the past month.
Anbio Biotechnology is a medical device company focused on in vitro diagnostics. It offers laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions to detect a wide range of biomarkers associated with critical medical domains encompassing infectious diseases, cancer, cardiovascular diseases, inflammation, drug abuse, endocrine disorders, renal disease, pharmacogenomics, and diabetes. Its product portfolio comprises AF-1200 Fluorescence Immunoassay Analyzer, SHA-100 Dry Chemistry Analyzer, Ferritin Rapid Test Kit, Dengue NS1 Rapid Test, Multi-HBV Rapid Test, COVID-19 Test Kit (Real-time PCR), and others. Geographically, the company generates maximum revenue from the European Union, followed by South America, Asia Pacific, North America, and other regions.
See More
Previous Close:
$7.87
Open:
$7.85
24h Volume:
19,176
Relative Volume:
0.23
Market Cap:
$347.39M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+4.16%
1M Performance:
+24.73%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$7.82
$8.05
1-Week Range:
$7.50
$8.05
52-Week Range:
$5.60
$8.22
Anbio Biotechnology Stock (NNNN) Company Profile
Name
Anbio Biotechnology
Sector
Industry
Phone
-
Address
-
Compare NNNN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NNNN
Anbio Biotechnology
|
7.915 | 336.21M | 0 | 0 | 0 | 0.00 |
|
ISRG
Intuitive Surgical Inc
|
553.23 | 197.20B | 8.71B | 2.48B | 1.75B | 6.82 |
|
BDX
Becton Dickinson Co
|
169.36 | 50.02B | 20.87B | 1.50B | 2.59B | 5.24 |
|
ALC
Alcon Inc
|
85.18 | 42.88B | 9.93B | 1.12B | 1.58B | 2.25 |
|
RMD
Resmed Inc
|
244.13 | 36.10B | 5.02B | 1.31B | 1.56B | 8.91 |
|
BAX
Baxter International Inc
|
29.55 | 15.84B | 11.89B | -560.00M | 191.00M | -1.10 |
Anbio Biotechnology Stock (NNNN) Latest News
Anbio Biotechnology to Showcase Global Diagnostic Innovations at Three Major May Exhibitions - The Manila Times
Anbio Biotechnology to Showcase Innovative Diagnostic Solutions at Key International Exhibitions in May 2025 - Nasdaq
Anbio Expands Global Diagnostics Reach: 90+ Tests, 100+ Countries, and 3 Major Exhibition Debuts - Stock Titan
Highest quarter in years as med-tech raises $8B in Q1 financings - BioWorld MedTech
Financing Quarterly Statistics, Q1 2025 - insights.citeline.com
US Market's Undiscovered Gems and 2 Other Promising Small Caps - Yahoo Finance
Unveiling US Market's Undiscovered Gems April 2025 - simplywall.st
Uncovering Hidden Opportunities In US With These 3 Undiscovered Gems - Yahoo Finance
US Market's Undiscovered Gems Featuring ZJK Industrial And 2 More Small Caps - simplywall.st
US Undiscovered Gems to Explore in April 2025 - Yahoo Finance
Discovering US Market's Undiscovered Gems April 2025 - simplywall.st
US Undiscovered Gems To Explore In April 2025 - Yahoo Finance
Undiscovered Gems in the US Market for April 2025 - simplywall.st
US Market's Undiscovered Gems for April 2025 - simplywall.st
Exploring US Undiscovered Gems In April 2025 - simplywall.st
3 Undiscovered Gems In The US Market - simplywall.st
Discovering 3 US Undiscovered Gems with Strong Potential - simplywall.st
US Undiscovered Gems To Watch In April 2025 - simplywall.st
Lamb Weston Posts Better-Than-Expected Results, Joins Sanofi And Other Big Stocks Moving Higher On Thursday - Benzinga
Discovering US Undiscovered Gems In April 2025 - simplywall.st
Discovering 3 Undiscovered Gems In The US Market - simplywall.st
US Market Undiscovered Gems To Explore In March 2025 - simplywall.st
US Market's Top 3 Undiscovered Gems With Strong Potential - simplywall.st
Discovering US Undiscovered Gems in March 2025 - Simply Wall St
US Market's Top 3 Undiscovered Gems with Strong Fundamentals - Simply Wall St
Uncovering 3 Undiscovered Gems In The US Market - Simply Wall St
US Market's Undiscovered Gems for March 2025 - Simply Wall St
IPO Roundup: Advanced Biomed, Brag House Holdings and more - MSN
Amaran Biotech Signs MOU with Nippon Fine Chemical - GlobeNewswire Inc.
Is the IPO Market Shutting Down? - Cabot Wealth Network
Kestra Medical ups IPO target to $150M - BioWorld Online
Unlocking Anbio's IPO: A Pivotal Shift in Global Diagnostics! - Mi Valle
U.S. IPO Weekly Recap: IPO Calendar Slows Down With Small Listings - Seeking Alpha
IPO NewsUS IPO Weekly Recap: IPO calendar slows down with small listings - Renaissance Capital
Undiscovered Gems In The US Featuring Anbio Biotechnology And 2 Other Small Caps - Yahoo Finance
Fresh Biotech Player Enters Nasdaq: Will Anbio's $8M IPO Fuel Its Global Expansion? - Stock Titan
Anbio Biotechnology's IPO opens up 5% By Investing.com - Investing.com South Africa
Anbio Biotechnology’s IPO opens up 5% By Investing.com - Investing.com Australia
Anbio Biotechnology Share Price | NASDAQ: NNNN Stock - Investing.com UK
Anbio Biotechnology's IPO opens up 5% - Investing.com
Anbio Biotechnology’s IPO Set to Revolutionize Global Diagnostics - Mi Valle
NNNNANBIO BIOTECHNOLOGY Latest Stock News & Market Updates - Stock Titan
Anbio Biotechnology to Showcase Cutting-Edge Diagnostic Solutions at 2025 Medlab Middle East - PR Newswire
Anbio Biotechnology Unveils Dry Chemiluminescence Immunoassay (CLIA) Solution: Redefining Diagnostic Precision and Efficiency - PR Newswire
Anbio Biotechnology Pursues U.S. IPO For Its IVD Products Launch - Seeking Alpha
NNNN IPO NewsGermany-based diagnostics products developer Anbio Biotechnology files for a $9 million US IPO - Renaissance Capital
Anbio Biotechnology Unveils Comprehensive In-Vitro-Diagnostics Solutions at ADLM 2024 - PR Newswire
Enzyme Immunoassay Market Size to Hit USD 26.55 Billion by 2033 - BioSpace
Anbio Biotechnology to Showcase at ADLM 2024 with Evolved In Vitro Diagnostic Solutions - PR Newswire
Anbio advances POC testing with new FIA analyzer - SelectScience
Anbio Breaks New Ground in Europe with Advanced “Point of Care” Diagnostic Tools - Columnist24
Anbio Biotechnology Stock (NNNN) Financials Data
There is no financial data for Anbio Biotechnology (NNNN). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
0.47%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):